These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28089969)

  • 1. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.
    Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA
    J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
    Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
    Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature.
    Behrens F; Cañete JD; Olivieri I; van Kuijk AW; McHugh N; Combe B
    Rheumatology (Oxford); 2015 May; 54(5):915-26. PubMed ID: 25349441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.
    Manders SH; Kievit W; Jansen TL; Stolk JN; Visser H; Schilder AM; Vonkeman HE; Adang E; van de Laar MA; van Riel PL
    J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
    Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
    RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.
    Thomas ML; Shaddick G; Charlton R; Cavill C; Holland R; Iannone F; Lapadula G; Lopriore S; Závada J; Uher M; Pavelka K; Szczuková L; Sidiropoulos P; Flouri I; Drosos A; Möller B; Nissen MJ; Müller RB; Scherer A; McHugh N; Nightingale A
    J Rheumatol; 2021 Jan; 48(1):48-57. PubMed ID: 32238520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
    Mease PJ; Stryker S; Liu M; Salim B; Rebello S; Gharaibeh M; Collier DH
    Arthritis Res Ther; 2021 Sep; 23(1):236. PubMed ID: 34496952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.
    Mease PJ; Collier DH; Saunders KC; Li G; Kremer JM; Greenberg JD
    RMD Open; 2015; 1(1):e000181. PubMed ID: 26819748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
    Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
    Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
    Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
    Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
    Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
    Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
    Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
    Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.